LionBird

LionBird is a venture capital firm investing in pre-scale digital health companies.

Venture Capital Active Tel Aviv-Yafo, Israel Est. 2012
Visit website ↗ LinkedIn
Last updated 2026-07-20
Portfolio
0
in our dataset
Rounds participated
0
Rounds led
0
Rounds' value
—
total disclosed, rounds participated
Stages
A Round, B Round, Pre-Seed, Seed

About

LionBird is a venture capital firm founded in 2012 with operations in Tel Aviv, Israel, and the U.S.. The firm invests in pre-scale digital health companies, providing capital and assistance to teams focused on realigning the human-technology relationship in healthcare. LionBird aims to help founders build strong foundations for their companies to scale and succeed. Their investment strategy emphasizes supporting teams with a deep understanding of the healthcare context and the ability to deliver effective solutions, particularly those utilizing artificial intelligence to enhance patient care. LionBird has invested in over 30 founding teams across the U.S. and Israel since its inception.

Portfolio

No portfolio companies in this dataset yet.

Investment activity

5 portfolio exits on record.

Portfolio by sector

Health Tech & Life Sciences20
Business Software5
Fintech & Insurtech3

Funds · 3

  • 3 — $85M Apr 2022
  • 2 — $35M Jul 2017
  • 1 — $20M Oct 2013

Q&A

What is LionBird's primary investment focus?
LionBird is a venture capital firm that exclusively invests in early-stage digital health companies, with operations in Tel Aviv and the U.S.
When did LionBird close its most recent fund, and what was its size?
LionBird closed its third fund, Fund 3, in April 2022, raising $85 million. This fund is exclusively focused on early-stage digital health.
Can you name a recent notable exit for LionBird?
In January 2024, LionBird saw an exit with the acquisition of C2i Genomics by Veracyte for $95 million. C2i Genomics is a whole-genome cancer treatment intelligence platform.
Which sectors does LionBird primarily invest in?
LionBird's portfolio shows a strong concentration in Health Tech & Life Sciences, accounting for 20 of its portfolio companies. They also have investments in Business Software and Fintech & Insurtech.
Who are the managing partners at LionBird?
The managing partners at LionBird are Chaim Friedman and Edward Michael, both of whom are also founders of the firm.
What are some of LionBird's recent investments in the digital health space?
LionBird has recently invested in companies like Chiefy, a clinical communication and collaboration system, and Jimini Health, which focuses on AI-supported therapy, both founded in 2023.
What investment stages does LionBird typically target?
LionBird primarily targets Pre-Seed, Seed, A Round, and B Round investments. Their most frequent investments are at the Seed stage.
Has LionBird had any other significant exits in the past two years?
Yes, in January 2022, LionBird had an exit with the acquisition of PhysiMax Technologies by DarioHealth for $6 million. PhysiMax Technologies offers an AI-powered musculoskeletal self-assessment platform.
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)